Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their price objective on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Piper Sandler reduced their price objective on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and set a $13.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Lake Street Capital cut their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Thursday, October 31st.

Alphatec Price Performance

ATEC opened at $9.40 on Friday. The stock has a fifty day moving average price of $6.07 and a 200 day moving average price of $8.52. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec has a 1 year low of $4.88 and a 1 year high of $17.34. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -7.34 and a beta of 1.31.

Insider Transactions at Alphatec

In other Alphatec news, Director David M. Demski bought 50,000 shares of the stock in a transaction on Wednesday, August 21st. The shares were purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares of the company’s stock, valued at $1,635,460.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 22.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Alphatec

A number of hedge funds have recently bought and sold shares of the stock. Net Worth Advisory Group bought a new stake in shares of Alphatec in the 3rd quarter worth approximately $76,000. Comerica Bank raised its stake in shares of Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after purchasing an additional 2,534 shares in the last quarter. Van ECK Associates Corp lifted its position in Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after purchasing an additional 6,998 shares during the period. Tempus Wealth Planning LLC acquired a new stake in Alphatec during the third quarter worth $107,000. Finally, Atria Investments Inc increased its holdings in Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after buying an additional 1,460 shares during the period. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.